They didn't get the results they wanted in one of their pipeline drugs. In response, sp tanked causing company to revisit their business strategy going forward. Looks like the 'excess overhead' is being sent along their way as the company restructure. They're looking to out-license the lesser pipeline assets for continued development while focusing on their core portfolio of oncology pipeline drugs.
Someone else posted they may be prepping the way for an RM. I do believe a takeover of one form or another is underway. Thus the Form 4's..>Next- company update on their plans.
News 
Market Data 
Discover 
